Team:Calgary/Project/OurSensor/Reporter/BetaLactamase
From 2013.igem.org
Line 69: | Line 69: | ||
<p><b>Figure 6. </b>Absorbance values at 600nm for each tube at four different time points: 0, 30, 60 and 120min. The cultures that expressed β-lactamase (<a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189007"><span class="Green"><b>BBa_K1189007</b></span></a>) showed higher absorbance levels, showing that the cells were able to grow in the presence of ampicillin.</a> | <p><b>Figure 6. </b>Absorbance values at 600nm for each tube at four different time points: 0, 30, 60 and 120min. The cultures that expressed β-lactamase (<a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189007"><span class="Green"><b>BBa_K1189007</b></span></a>) showed higher absorbance levels, showing that the cells were able to grow in the presence of ampicillin.</a> | ||
</figcaption> | </figcaption> | ||
- | <p>After confirming protein expresison, we were able to purify both our β-lactamase (<a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189007"><span class="Green"><b>BBa_K1189007</b></span></a>) and our TALE-A-<i>amp</i>R fusion protein (<a href=" http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189031"><span class="Green"><b>BBa_K1189031</b></span></a>)(Figure 7). We were then able to demonstrate that β-lactamase retained its enzymatic activity in both purfiied products. This was tested by a variation of the ampicillin survival assay where we pretreated, LB containing ampicillin and chloramphenicol, with our purified TALE A linked to β-lactamase (<a href=" http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189031"><span class="Green"><b>BBa_K1189031</b></span></a>). We then cultured bacteria in the treated LB carrying the psB1C3 (<a href="http://parts.igem.org/Part:pSB1C3"><span class="Green | + | <p>After confirming protein expresison, we were able to purify both our β-lactamase (<a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189007"><span class="Green"><b>BBa_K1189007</b></span></a>) and our TALE-A-<i>amp</i>R fusion protein (<a href=" http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189031"><span class="Green"><b>BBa_K1189031</b></span></a>) (Figure 7). We were then able to demonstrate that β-lactamase retained its enzymatic activity in both purfiied products. This was tested by a variation of the ampicillin survival assay where we pretreated, LB containing ampicillin and chloramphenicol, with our purified TALE A linked to β-lactamase (<a href=" http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189031"><span class="Green"><b>BBa_K1189031</b></span></a>). We then cultured bacteria in the treated LB carrying the psB1C3 (<a href="http://parts.igem.org/Part:pSB1C3"><span class="Green><b>pSB1C3</b></span></a>), conveying resistance to chloramphenicol. Therefore, the bacteria are only able to survive if our isolated protein retained its enzymatic abilities. We can show that the bacteria susceptible to ampicillin were able to grow in the presence of our purified proteins (<a href=" http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189031"><span class="Green"><b>BBa_K1189031</b></span></a>), which means that we are expressing and purifying functional protein which is degrading the ampicillin (Figures 8). Both graphs show an increase in OD for cultures pre-treated with our protein demonstrating our protein is functional.</p> |
- | pSB1C3 | + | |
- | </b></span> | + | |
- | </a>), conveying resistance to chloramphenicol. Therefore, the bacteria are only able to survive if our isolated protein retained its enzymatic abilities. We can show that the bacteria susceptible to ampicillin were able to grow in the presence of our purified proteins (<a href=" http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189031"><span class="Green"><b>BBa_K1189031</b></span></a>), which means that we are expressing and purifying functional protein which is degrading the ampicillin (Figures 8). Both graphs show an increase in OD for cultures pre-treated with our protein demonstrating our protein is functional.</p> | + | |
<figure> | <figure> | ||
<img src="https://static.igem.org/mediawiki/2013/4/45/YYC2013_TALE_September_22_Blac.jpg"> | <img src="https://static.igem.org/mediawiki/2013/4/45/YYC2013_TALE_September_22_Blac.jpg"> | ||
Line 80: | Line 77: | ||
beat beating | beat beating | ||
</b></span> | </b></span> | ||
- | </a> and <a href="https://2013.igem.org/Team:Calgary/Notebook/Protocols/OsmoticShock"><span class="Green"><b>sucrose osmotic shock</b></span></a> respectively. On the right, western blot of <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K782004"><span class="Green"><b>TALE A</b></span></a>-linker-β-lactamase (<a href=" http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189031"><span class="Green"><b>BBa_K1189031</b></span></a>) showing that we were able to express and purify our | + | </a> and <a href="https://2013.igem.org/Team:Calgary/Notebook/Protocols/OsmoticShock"><span class="Green"><b>sucrose osmotic shock</b></span></a> respectively. On the right, western blot of <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K782004"><span class="Green"><b>TALE A</b></span></a>-linker-β-lactamase (<a href=" http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189031"><span class="Green"><b>BBa_K1189031</b></span></a>) showing that we were able to express and purify our fusion protein. |
</figcaption> | </figcaption> | ||
<figure> | <figure> | ||
Line 93: | Line 90: | ||
</figcaption> | </figcaption> | ||
<p>After verifying that <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K782004"><span class="Green"><b>TALE A</b></span></a>-linker-β-lactamase (<a href=" http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189031"><span class="Green"><b>BBa_K1189031</b></span></a>) retained enzymatic activity and was able to degrade ampicillin, we performed a <a href="https://2013.igem.org/Team:Calgary/Notebook/Protocols/BenzylpenicillianAssay"><span class="Green"><b> | <p>After verifying that <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K782004"><span class="Green"><b>TALE A</b></span></a>-linker-β-lactamase (<a href=" http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189031"><span class="Green"><b>BBa_K1189031</b></span></a>) retained enzymatic activity and was able to degrade ampicillin, we performed a <a href="https://2013.igem.org/Team:Calgary/Notebook/Protocols/BenzylpenicillianAssay"><span class="Green"><b> | ||
- | + | pH assay</b></span></a> using benzylpenicillin as our substrate. We were able to see a colour change due to the presence of phenol red, a pH indicator with a transition pH of 6.8-8.2, turning red at lower pH. β-lactamase hydrolyzes benzylpenicillin to penicillinoic acid, which changes the pH of the solution from alkaline to acidic. This pH change causes the phenol red to change from red to yellow. Our negative controls, to which benzylpenicillin was not added, remained red. We can also see the colour change coincides with the amount of purified TALE A-β-lactamase present in each sample (Figure 10).</p> | |
<figure> | <figure> | ||
<img src="https://static.igem.org/mediawiki/2013/8/86/YYC2013_Blac_%2B_Penicillium_G.jpg"> | <img src="https://static.igem.org/mediawiki/2013/8/86/YYC2013_Blac_%2B_Penicillium_G.jpg"> | ||
Line 101: | Line 98: | ||
</figcaption> | </figcaption> | ||
- | <p> Therefore, we have built and submitted β-lactamase both on its own and linked to TALE A. We | + | <p> Therefore, we have built and submitted parts containing β-lactamase, both on its own and linked to TALE A. We then expressed, purified and demonstrated the final purified products have retained their enzymatic activity. We can show activity for our mobile TALE A linked to β-lactamase (<a href=" http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189031"><span class="Green"><b>BBa_K1189031</b></span></a>) for our sensor in two different ways, through pH and cell growth assays.</p> |
+ | <p> | ||
</section> | </section> | ||
</html> | </html> |
Revision as of 19:02, 27 October 2013
β-Lactamase
β-Lactamase
What is β-lactamase?
β-lactamase is an enzyme encoded by the ampicillin resistance gene (ampR) frequently present in plasmids for selection. Structurally, β-lactamase is a 29 kDa monomeric enzyme (Figure 1). Its enzymatic activity provides resistance to β-lactam antibiotics such as carbapenems, penicillin and ampicillin through hydrolysis of the β-lactam ring, a structure shared by the β-lactam class of antibiotics (Qureshi, 2007).
Many advantages come from working with β-lactamase. It shows high catalytic efficiency and simple kinetics. Also, no orthologs of ampR are known to be encoded by eukaryotic cells and no toxicity was identified making this protein very useful in studies involved eukaryotes (Qureshi, 2007). β-lactamase has been used to track pathogens in infected murine models (Kong et al., 2010). However, in addition to its application in eukaryotic cells, ampR has been found to have an alternative application in synthetic proteins as well. ampR is able to preserve its activity when fused to other proteins, meaning it can viably be used in fusion proteins (Moore et al., 1997). This feature makes β-lactamase a potentially valuable tool for assembly of synthetic constructs.
How is β-lactamase used as a Reporter?
β-lactamase, in the presence of different substrates, can give various outputs. It can produce a fluorogenic output in the presence of a cephalosporin derivative (CCF2/AM), which can then subsequently be measured using a fluorometer (Remy et al., 2007).
Besides fluorescence assays, β-lactamase can also be used to obtain colourimetric outputs by breaking down synthetic compounds such as nitrocefin (Figure 2). The result of nitrocefin hydrolysis is a colour change from yellow to red(Remy et al., 2007). Alternatively, colourimetric assays can also be done using β-lactamase. One example is the use of benzylpenicillin as the substrate, which gives a pH output that can be detected with pH indicators to give a colourimetric output (Li et al., 2008).